Total Health

Anthony S. Fauci, M.D.

Director, NIAID

Anthony S. Fauci, M.D. is director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where he oversees an extensive research portfolio focused on infectious and immune-mediated diseases. He serves as one of the key advisors to the White House and Department of Health and Human Services on global HIV/AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats. He is the winner of numerous prestigious awards including the Presidential Medal of Freedom, the National Medal of Science and the Lasker Award for Public Service.

Arianna Huffington

Chief Executive Officer, Thrive Global

Arianna Huffington is the founder and CEO of Thrive Global, the founder of The Huffington Post, and the author of 15 books, including, most recently, Thrive and The Sleep Revolution. In 2016, she launched Thrive Global, a leading behavior change tech company with the mission of changing the way we work and live by ending the collective delusion that burnout is the price we must pay for success.

She has been named to Time Magazine's list of the world’s 100 most influential people and the Forbes Most Powerful Women list. Originally from Greece, she moved to England when she was 16 and graduated from Cambridge University with an M.A. in economics. At 21, she became president of the famed debating society, the Cambridge Union.

She serves on numerous boards, including Onex and The B Team.

Her last two books, Thrive: The Third Metric to Redefining Success and Creating a Life of Well-Being, Wisdom, and Wonder and The Sleep Revolution: Transforming Your Life, One Night At A Time, both became instant international bestsellers.

Anne Wojcicki

CEO and co-founder, 23andMe

Anne co-founded 23andMe in 2006 after a decade spent in healthcare investing, focused primarily on biotechnology companies. Her hope was to empower consumers with access to their own genetic information and to create a way to generate more personalized information so that commercial and academic researchers could better understand and develop new drugs and diagnostics. Presently, 23andMe has built one of the world’s largest databases of individual genetic information. Its novel, web-based research approach allows for the rapid recruitment of participants to many genome-wide association studies at once, reducing the time and money needed to make new discoveries, and the company has created a proven and standardized resource for finding new genetic association and confirming genetic loci discovered by others. Under Anne’s leadership 23andMe has made significant advances in bringing personalized medicine directly to the public. Anne graduated from Yale University with a BS in Biology. Getting access to and understanding her own genetic information had always been one of her ambitions.

Michael J. Dowling

President and Chief Executive Officer, Northwell Health

Michael J. Dowling is President and Chief Executive Officer of Northwell Health (formerly the North Shore-LIJ Health System). With 21 hospitals, more than 450 outpatient physician practices and a full complement of long-term care services, Northwell Health is one of the nation’s largest health systems, with nearly $8 billion in annual revenue. Michael served in New York State government for 12 years, including seven years as state director of Health, Education and Human Services and deputy secretary to the governor. He was also commissioner of the New York State Department of Social Services. Earlier this month, Mr. Dowling spoke to the audience of the HEP Annual Meeting about issues affecting large hospital systems, the healthcare industry in general, and the Hofstra Northwell School of Medicine.

Michael A. Slubowski

President and Chief Executive Officer, Trinity Health

Mike Slubowski, president and chief executive officer, Trinity Health provides executive leadership to the 22-state, 92-hospital Catholic health system, serves on the Trinity Health Board of Directors, and has full accountability for the overall achievement, advancement, and success of the system.

Immediately prior to this role, Slubowski served as the system's president and chief operating officer, overseeing all system operations, and focusing on ensuring that people, processes, IT systems and resources were in place to achieve successful operations.

Slubowski's more than 40 years as a health care executive include tenures as president and CEO of Sisters of Charity of Leavenworth Health System, in Colorado, as president, Health Networks, for Trinity Health before its 2013 merger with Catholic Health East, and in executive leadership positions at health systems including Henry Ford Health System in Detroit, Michigan; Samaritan Health Services in Phoenix, Arizona; and Providence Hospital in Southfield, Michigan.

Slubowski holds a bachelor's degree in business administration and a master’s degree in business administration from Wayne State University in Detroit, Michigan. He completed advanced health care leadership training through an Advanced Leadership Institute conducted by the University of Michigan School of Business and sponsored by the National Center for Healthcare Leadership. He also holds fellowships in the American College of Healthcare Executives and the American College of Medical Practice Executives.

Paul Stoffels

Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.

Paul spearheads the Johnson & Johnson research and product pipeline by leading teams across all our sectors to set the companywide innovation agenda, discovering and developing transformational healthcare solutions. He also is responsible for the safety of all products of the Johnson & Johnson Family of Companies worldwide, and steers the company’s global public health strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.

Paul’s commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions. Paul also oversees JJDC, the oldest corporate venture fund in the life science industry.

Previously, in his role as Worldwide Chairman, Pharmaceuticals, Paul led the transformation of the pharmaceutical research and development pipeline for Janssen Pharmaceutical Companies of Johnson & Johnson, driving a fundamental shift in the R&D paradigm that is now a model in the industry for productivity and innovation. Under his leadership, Janssen rejuvenated its pipeline, launching multiple new medicines and making a difference for people all over the world.

Prior to this, Paul held various R&D leadership roles within the pharmaceutical sector of Johnson & Johnson. He joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec, and led the development of several breakthrough products for the treatment of HIV that helped to transform this devastating disease from a death sentence to a chronic and treatable condition.

Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium. He began his career as a physician in Africa, focusing on HIV and tropical diseases research.

Greg A. Adams

Chairman and Chief Executive Officer, Kaiser Permanente

Greg A. Adams is the chairman and CEO of Kaiser Foundation Health Plan, Inc. and Hospitals.

Adams assumed the role of chairman and CEO in December 2019.

A nationally recognized leader and a champion of health care transformation, improving access, and pushing for better health outcomes, Adams, since his time with Kaiser Permanente, has been driving the comprehensive work focused on growing the organization’s membership, improving affordability for members, and transforming and expanding access to care.

Adams has 30 years of leadership experience as a senior health care executive and has played an integral role in leading the transformation and improvement of patient care outcomes at Kaiser Permanente. In addition, Adams has been a key leader in driving the organization’s mission of providing high-quality, affordable care and coverage; strengthening the culture; and ensuring Kaiser Permanente continues to be a great place to work.

Prior to his current role, Adams served as executive vice president and group president, with direct responsibility for health plan and hospital operations in all 8 Kaiser Permanente regions, serving 12.4 million members and operating 39 hospitals and 715 medical office facilities. Adams' accountabilities included co-leading Enterprise Shared Services to serve the operational needs of the regions and leading Kaiser Permanente’s national Medicare care delivery strategy. Prior to that, he was named regional president of Kaiser Permanente for Northern California in April 2008. In July 2013, he was appointed executive vice president.

Adams is a member of the board of directors for America’s Health Insurance Plans and is both a governor and steward within the Global Health and Healthcare Community at the World Economic Forum. Additionally, Adams is a member of the Business Roundtable, the National Association of Health Services Executives, and The Executive Leadership Council. He also serves on the board of directors for the Los Angeles Philharmonic Association. He is a past member of the California Chamber of Commerce board of directors and the California Hospital Association’s board of trustees.

Adams has a bachelor’s degree from Oglethorpe University in Atlanta and graduate degree from Wichita State University.

George Yancopoulos

Chief Scientific Officer, Regeneron

George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s seven FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene® and VelocImmune®. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly-productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the "most innovative companies in the world" by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.

Dr. Anton Decker

President, International, Mayo Clinic

G. Anton Decker, MBBCh, is president of International at Mayo Clinic, a not-for-profit, academic health system. With a workforce of 70,000, Mayo Clinic earns $14 billion in annual revenue while caring for more than 1.2 million patients each year from all 50 states and more than 140 countries.

Prior to returning to Mayo Clinic in 2019, Dr. Decker was president of Health Innovation for Bon Secours Mercy Health, an $8 billion net revenue international health system with 48 hospitals and 60,000 staff. He also served as chief clinical officer for Mercy Health, president of Mercy Health Physicians, chief medical officer and board chair for Banner Medical Group, and board chair for Banner Health Network.

Dr. Decker, a gastroenterologist, has authored more than 60 peerreviewed papers and has been an invited speaker at numerous institutions and meetings, most with a focus on health care economics. He is the chair of the American Gastroenterological Association Practice Management and Economics Committee.

Born in South Africa, Dr. Decker completed medical school at the University of the Witwatersrand, Johannesburg, and trained at Mayo Clinic College of Medicine and Science as a resident and fellow. He also earned a master’s degree in health administration.

Having worked in four countries, Dr. Decker brings a global perspective to collaboration with people from all backgrounds and experiences.

Christophe Weber

President and Chief Executive Officer, Takeda Pharmaceutical Company Limited

Christophe Weber is President, Chief Executive Officer (CEO) and Representative Director of Takeda Pharmaceutical Company Ltd. He joined the company in April 2014 as Chief Operating Officer, was named President and Representative Director in June 2014, and was subsequently appointed CEO in April 2015. Mr. Weber has focused on Takeda’s R&D transformation and globalization, creating a diverse and inclusive working environment while strengthening its ethical values and corporate governance. Through this transformation, Takeda became one of the leading global biopharmaceutical companies in the world.

Prior to joining Takeda, Mr. Weber spent 20 years at GlaxoSmithKline (GSK), where he held senior leadership roles in Europe, Asia and the United States.

Outside of Takeda, Mr. Weber is member of The Business Council, the World Economic Forum’s International Business Council, the Singapore Economic Development Board’s International Advisory Council, the New York Stock Exchange’s NYSE Board Advisory Council and the MIT CEO Advisory Board. He also serves on the Board of Trustees of Northeastern University.

Mr. Weber holds a doctorate in pharmacy and pharmacokinetics, master’s degrees in pharmaceutical marketing and in accounting and finance and a degree in statistics, from the University of Lyon, France.

Mr. Weber lives in Tokyo with his wife and has two children.